Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US RE46,284 In forceTerm ends Sep 22, 2029 · From the USPTO record
20-year base term ended Jan 26, 2025
Jan 26, 2005
Sep 22, 2029
Jan 24, 2017
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 26, 2005, when the earliest non-provisional application in its chain was filed (this one was filed Dec 30, 2015) | Jan 26, 2025 | From the USPTO record |
| Continuity chain | A reissue: its term follows the original patent's, with the original's term adjustment | follows the original patent | From the USPTO record |
| Patent term adjustment | +688 days, the original patent's USPTO patent term adjustment record, which governs a reissue (35 U.S.C. 251). This reissue's own record carries none | Dec 15, 2026 | From the USPTO record |
| Terminal disclaimer cap | None on record | no cap applied | From the USPTO record |
| Patent term extension | +1012 days, USPTO 35 U.S.C. 156 certificate | added to Dec 15, 2026: Sep 22, 2029 | From the USPTO record |
| Fee events | 3 of 3 maintenance fees paid | In force | From the USPTO record |
| Computed term end | The steps above, in order | Sep 22, 2029 | From the USPTO record |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.